This article is more than 5 years old. Information may no longer be current.

Lobo to lead Stryker’s new neurotechnology and spine group

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Stryker Corporation announced the appointment of Kevin Lobo as a group president to lead their newly formed neurotechnology and spine group, according to a company press release.

Lobo joins Stryker after nearly a decade at Johnson & Johnson, where he held a number of senior-level leadership roles, most recently as worldwide president of Ethicon Endo-Surgery.

The moves follow Stryker’s acquisition of Boston Scientific’s neurovascular division. The new group includes Stryker’s neurovascular and spine divisions, the press release noted.

“The creation of our new neurotechnology and spine group will enable us to bring stronger alignment to these exciting market segments, and better serve the evolving needs of our surgeon customers in these innovative areas,” Stephen P. MacMillan, chairman, president and chief executive officer of Stryker Corporation, stated in the release. “Kevin’s record of delivering business results, his strong customer focus and his global leadership abilities are ideally suited for ensuring we capitalize on the many opportunities the neurotechnology and spine markets present our organization.”